Alembic Pharmaceuticals share news, announcements and annual reports
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 29 Oct 2026. Previous close ₹782.80.
29 Oct: open ₹780.40, high ₹801.00, low ₹776.00
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,624 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.75
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.51%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 63,49050.3% delivered
Alembic Pharmaceuticals analyst meets
94 filed, newest first. Page 2 of 2.
Jul 2022
27 Jul · Analysts
May 2022
13 May · Analysts
Apr 2022
28 Apr · Analysts
21 Apr · Analysts
Jan 2022
28 Jan · Analysts
Oct 2021
29 Oct · Analysts
Sep 2021
6 Sep · Analysts
Aug 2021
23 Aug · Analysts
16 Aug · Analysts
2 Aug · Analysts
2 Aug · Analysts
Jul 2021
15 Jul · Analysts
Jun 2021
3 Jun · Analysts
May 2021
13 May · Analysts
12 May · Analysts
Apr 2021
27 Apr · Analysts
Jan 2021
12 Jan · Analysts
Oct 2020
19 Oct · Analysts
14 Oct · Analysts
Jul 2020
22 Jul · Analysts
17 Jul · Analysts
11 Jul · Analysts
6 Jul · Analysts
4 Jul · Analysts
Apr 2020
16 Apr · Analysts
Mar 2020
19 Mar · Analysts
Jan 2020
8 Jan · Analysts
Oct 2019
14 Oct · Analysts
Aug 2019
19 Aug · Analysts
Jul 2019
18 Jul · Analysts
Apr 2019
22 Apr · Analysts
Mar 2019
1 Mar · Analysts
Jan 2019
Oct 2018
11 Oct · Analysts
Jul 2018
18 Jul · Analysts
May 2018
7 May · Analysts
Jan 2018
22 Jan · Analysts
Oct 2017
26 Oct · Analysts
Jul 2017
12 Jul · Analysts
Apr 2017
18 Apr · Analysts
Jan 2017
17 Jan · Analysts
Oct 2016
17 Oct · Analysts
Jul 2016
21 Jul · Analysts
Apr 2016
21 Apr · Analysts